Market Overview

Aetna Reports First-Quarter 2017 Results

Share:





Aetna (NYSE:AET) announced a first-quarter 2017 net loss(1) of
$381 million, or $1.11 per share, and adjusted earnings(2) of
$939 million, or $2.71 per share. Aetna's first-quarter 2017 results
reflect a strong start to the year despite costs associated with the
termination of the Humana Merger Agreement, which was the primary driver
of the first-quarter 2017 net loss.

"Our first quarter performance demonstrates the power of the disciplined
execution of Aetna's strategy," said Mark T. Bertolini, Aetna chairman
and CEO. "This strong start to the year has enabled Aetna to absorb
continued pressure from our individual Commercial products while
increasing investment in our growth initiatives and raising our
full-year 2017 earnings per share projections."

"Our increased shareholder dividend and accelerated share repurchase
announced earlier this year speak to the strength of Aetna's capital
position and commitment to delivering strong returns for shareholders,"
said Shawn M. Guertin, Aetna executive vice president and chief
financial officer.

       

(In millions, except per share data)

 
First-Quarter 2017 Full-Year 2017
Revenue     Earnings     EPS Projected EPS(4)
 
GAAP $ 15,165 $ (381 ) $ (1.11 ) $4.48 to $4.68
 
Non-GAAP (Adjusted) $ 15,487 $ 939 $ 2.71 $8.80 to $9.00
 
Medical Membership totaled 22.4 million at March 31, 2017
 

Aetna presents both GAAP and non-GAAP financial measures in this press
release to provide investors with additional information. Effective
March 31, 2017, to more clearly differentiate between the GAAP and
non-GAAP financial measures used in this press release and Aetna's other
disclosures, Aetna changed the naming convention for its non-GAAP
financial measures from "operating" measures to "adjusted" measures. The
underlying calculations of Aetna's consolidated non-GAAP financial
measures did not change. Refer to footnotes (1) through (7)
for definitions of non-GAAP financial measures used in this press
release and pages 10 through 11 for reconciliations of the most directly
comparable GAAP financial measures to non-GAAP financial measures.

 
First-Quarter Financial Results at a Glance
 
    First-Quarter
(Millions, except per common share data) 2017     2016     Change
Total revenue $ 15,165 $ 15,693 (3 )%
Adjusted revenue(3) 15,487 15,694 (1 )%
Net (loss) income(1) (381 ) 737 (152 )%
Adjusted earnings(2) 939 821 14 %
 
Per share results:
Net (loss) income(1) $ (1.11 ) $ 2.08 (153 )%
Adjusted earnings(2) 2.71 2.32 17 %
 
Weighted average common shares - diluted (GAAP)(5) 343.8 353.8
Adjusted weighted average common shares - diluted (non-GAAP)(5) 346.2   353.8    
 

Total Company Results

Aetna's first-quarter 2017 results include several items that impact
comparability with results in prior periods. The impact of these items
resulted in a net loss for the period, despite strong overall results in
Aetna's underlying businesses, with the exception of Aetna's individual
Commercial products. These items include costs associated with the
termination of the Humana Merger Agreement and an expense related to
estimated future guaranty fund assessments as a result of Penn Treaty
being placed in liquidation. In addition, first-quarter 2017 results
reflect the temporary suspension of the health insurer fee ("HIF").
Pricing actions designed to recover the HIF and other ACA mandated fees
represented approximately 3 percent of Health Care premiums in 2016.
Aetna's first-quarter 2017 results also include the impact of reduced
participation on the ACA's individual public health insurance exchanges.

  • Net loss(1) was $381 million for
    first-quarter 2017 compared with net income of $737 million for
    first-quarter 2016. The net loss during first-quarter 2017 compared
    with net income during first-quarter 2016 was primarily due to
    first-quarter 2017 reflecting costs associated with the termination of
    the Humana Merger Agreement.
  • Adjusted earnings(2) were $939 million for
    first-quarter 2017 compared with $821 million for first-quarter 2016.
    The double-digit percentage increase in adjusted earnings during
    first-quarter 2017 was primarily due to strong performance in Aetna's
    Health Care segment, despite the continued pressure in Aetna's
    individual Commercial products described below.
  • Total revenue and adjusted revenue(3)
    were $15.2 billion and $15.5 billion, respectively, for
    first-quarter 2017 and both $15.7 billion for first-quarter 2016. The
    decrease in total revenue and adjusted revenue was primarily due to
    lower premiums in Aetna's Health Care segment, including lower
    membership in Aetna's ACA compliant individual and small group
    products and the temporary suspension of the HIF in 2017, partially
    offset by higher premium yields in Aetna's Commercial business and
    membership growth in Aetna's Government business, each in Aetna's
    Health Care segment. The decrease in total revenue during
    first-quarter 2017 also was due to a realized capital loss during
    first-quarter 2017 of $336 million pre-tax due to unamortized cash
    flow hedge losses being recognized into earnings upon the redemption
    of certain of Aetna's senior notes.
  • Total company expense ratio was 25.4 percent and 18.2 percent
    for the first quarters of 2017 and 2016, respectively. The increase
    for first-quarter 2017 was primarily due to costs associated with the
    termination during first-quarter 2017 of the Humana Merger Agreement.
  • Adjusted expense ratio(6) was 16.0
    percent and 18.0 percent for the first quarters of 2017 and 2016,
    respectively. The improvement for first-quarter 2017 was primarily due
    to the temporary suspension of the HIF in 2017 and the execution of
    Aetna's expense management initiatives.
  • After-tax net loss margin was 2.5 percent for first-quarter
    2017 compared with after-tax net income margin of 4.7 percent for
    first-quarter 2016. The after-tax net loss margin for first-quarter
    2017 compared with after-tax net income margin for first-quarter 2016
    was primarily due to costs associated with the termination during
    first-quarter 2017 of the Humana Merger Agreement.
  • Adjusted pre-tax margin(7) was 10.0
    percent and 9.5 percent for the first quarters of 2017 and 2016,
    respectively. The increase was primarily due to strong performance in
    Aetna's Health Care segment, despite the continued pressure in Aetna's
    individual Commercial products described below, that more than offset
    the negative impact of the temporary suspension of the HIF in 2017.
  • Total debt to consolidated capitalization ratio(8) was
    39.8 percent at March 31, 2017 compared with 53.6 percent at
    December 31, 2016. The total debt to consolidated capitalization ratio
    at March 31, 2017 reflects the redemption of $10.2 billion aggregate
    principal amount of the senior notes issued in 2016, $750 million
    aggregate principal amount of senior notes due in 2020 and the
    repayment at maturity of $383 million aggregate principal amount of
    senior notes, each during first-quarter 2017.
  • Effective tax rate was 39.6 percent for first-quarter 2017
    compared with 42.7 percent for first-quarter 2016. The decrease in
    Aetna's effective tax rate for first-quarter 2017 was primarily due to
    the temporary suspension of the non-deductible HIF in 2017. Because
    Aetna was in a pre-tax loss position for first-quarter 2017, the
    decrease was partially offset by the deduction of transaction-related
    costs during first-quarter 2017.

Health Care Segment Results

Health Care, which provides a full range of insured and self-insured
medical, pharmacy, dental and behavioral health products and services,
reported:

  • Income before income taxes(1) of $1.2 billion for
    first-quarter 2017 compared with $1.4 billion for first-quarter 2016.
    The decrease in income before income taxes was primarily due to
    first-quarter 2017 reflecting a $231 million pre-tax expense related
    to estimated future guaranty fund assessments as a result of Penn
    Treaty being placed in liquidation. The decrease in income before
    incomes taxes in first-quarter 2017 also reflects the changes in
    pre-tax adjusted earnings described below.
  • Pre-tax adjusted earnings(2) remained relatively flat at
    approximately $1.5 billion for first-quarter 2017 and first-quarter
    2016, despite the negative impact of the temporary suspension of the
    HIF in 2017. Aetna's first-quarter 2017 results reflect strong
    performance across all of Aetna's Health Care businesses, with the
    exception of Aetna's individual Commercial products. During
    first-quarter 2017, Aetna recorded a $110 million premium deficiency
    reserve that reflects anticipated future losses for the 2017 coverage
    year in Aetna's individual Commercial products.
  • Total revenue and adjusted revenue(3) were both $14.8
    billion for first-quarter 2017 and both $15.0 billion for
    first-quarter 2016. The decrease in total revenue and adjusted revenue
    was primarily due to lower membership in Aetna's ACA compliant
    individual and small group products and the temporary suspension of
    the HIF in 2017, largely offset by higher premium yields in Aetna's
    Commercial business and membership growth in Aetna's Government
    business.
  • Medical membership at March 31, 2017 decreased by 664 thousand
    compared with December 31, 2016, primarily reflecting declines in
    Aetna's Commercial Insured products primarily related to Aetna's ACA
    compliant individual and small group products, partially offset by
    increases in Aetna's Commercial ASC products.
  • Medical benefit ratios ("MBRs") for first-quarter 2017 and 2016 were
    as follows:
                   
First-Quarter
2017     2016     Change
Commercial 79.4 % 77.8 % 1.6   pts.
Government 85.3 % 83.4 % 1.9   pts.
Total Health Care 82.6 % 80.5 % 2.1   pts.
 
  • Aetna's first-quarter 2017 Commercial MBR increased over first-quarter
    2016 primarily due to the temporary suspension of the HIF in 2017 and
    higher medical costs in Aetna's individual Commercial products,
    including a $110 million premium deficiency reserve. The increase was
    partially offset by improved performance in Aetna's group Commercial
    Insured products.
  • Aetna's first-quarter 2017 Government MBR increased compared with
    first-quarter 2016 primarily due to the temporary suspension of the
    HIF in 2017.
  • In first-quarter 2017, Aetna experienced favorable development of
    prior years' health care cost estimates in its Commercial, Medicaid
    and Medicare products, primarily attributable to fourth-quarter 2016
    performance.
  • Prior years' health care costs payable estimates developed favorably
    by $614 million and $627 million during the first quarters of 2017 and
    2016, respectively. This development is reported on a basis consistent
    with the prior years' development reported in the health care costs
    payable table in Aetna's annual audited financial statements, and does
    not directly correspond to an increase in 2017 operating results.
  • Days claims payable(8) was 53 days at March 31,
    2017, a decrease of four days compared with March 31, 2016 and a
    sequential decrease of one day compared to December 31, 2016. The year
    over year decrease was driven by a number of factors, including the
    operational maturation of new Medicaid contracts, decreased claims
    processing times and business mix, primarily related to the decline in
    Aetna's individual Commercial product membership.

Group Insurance Segment Results

Group Insurance, which includes group life, disability and long-term
care products, reported:

  • Income before income taxes(1) of $35 million for
    first-quarter 2017 compared with $28 million for first-quarter 2016.
    Pre-tax adjusted earnings(2) were $33 million for
    first-quarter 2017 compared with $25 million for first-quarter 2016.
    Income before income taxes and pre-tax adjusted earnings increased
    primarily due to higher net investment income.
  • Total revenue of $621 million and $612 million for the first quarters
    of 2017 and 2016, respectively. Adjusted revenue(3) was
    $619 million and $609 million for the first quarters of 2017 and 2016,
    respectively. Total revenue and adjusted revenue increased primarily
    due to higher premiums in Aetna's life and disability products and
    higher net investment income.

Large Case Pensions Segment Results

Large Case Pensions, which manages a variety of discontinued and other
retirement and savings products, primarily for qualified pension plans,
reported:

  • Income before income taxes(1) of $4 million for
    first-quarter 2017 compared with $3 million for first-quarter 2016.
    Pre-tax adjusted earnings(2) were $4 million for
    first-quarter 2017 compared with $1 million for first-quarter 2016.
  • Total revenue of $86 million and $67 million for the first-quarters of
    2017 and 2016, respectively. Adjusted revenue(3) was $86
    million and $65 million for the first quarters of 2017 and 2016,
    respectively. Total revenue and adjusted revenue increased primarily
    due to higher net investment income.

Aetna's conference call to discuss first-quarter 2017 results will
begin at 8:30 a.m. ET today. The public may access the conference call
through a live audio webcast available on Aetna's Investor Information
website at
www.aetna.com/investor.
Financial, statistical and other information, including GAAP
reconciliations, related to the conference call also will be available
on Aetna's Investor Information website.

The conference call also can be accessed by dialing 1-877-709-8150,
or +1-201-689-8354 for international callers. The company suggests
participants dial in approximately 10 minutes before the call. No access
code is required. Individuals who dial in will be asked to identify
themselves and their affiliations.

A replay of the call may be accessed through Aetna's Investor
Information website at
www.aetna.com/investor
or by dialing 1-877-660-6853, or +1-201-612-7415 for international
callers. The replay conference ID is 13659506.
Telephone replays
will be available until 11 p.m. ET on May 16, 2017.

About Aetna
Aetna is one of the nation's leading diversified
health care benefits companies, serving an estimated 44.9 million people
with information and resources to help them make better informed
decisions about their health care. Aetna offers a broad range of
traditional, voluntary and consumer-directed health insurance products
and related services, including medical, pharmacy, dental, behavioral
health, group life and disability plans, and medical management
capabilities, Medicaid health care management services, workers'
compensation administrative services and health information technology
products and services. Aetna's customers include employer groups,
individuals, college students, part-time and hourly workers, health
plans, health care providers, governmental units, government-sponsored
plans, labor groups and expatriates. For more information, see www.aetna.com
and learn about how Aetna is helping to build a healthier world.
@AetnaNews

 
Condensed Consolidated Balance Sheets
(Unaudited)
 
         
(Millions)

At March 31,
2017

At December 31,
2016

Assets:
Cash and short-term investments $ 6,956 $ 21,042
Accounts receivable, net 5,112 4,580
Other current assets 2,950   2,827
Total current assets 15,018   28,449
Long-term investments 21,922 21,833
Other long-term assets 19,411   18,864
Total assets $ 56,351   $ 69,146
 
Liabilities and shareholders' equity:
Health care costs payable $ 6,432 $ 6,558
Current portion of long-term debt 1,249 1,634
Other current liabilities 11,867   10,502
Total current liabilities 19,548   18,694
Long-term debt, less current portion 8,174 19,027
Other long-term liabilities 14,291 13,482
Total Aetna shareholders' equity 14,261 17,881
Non-controlling interests 77   62
Total liabilities and equity $ 56,351   $ 69,146
 
 
Consolidated Statements of Income
(Unaudited)
 
      For the Three Months
Ended March 31,
(Millions) 2017     2016
Revenue:
Health care premiums $ 13,219 $ 13,469
Other premiums 544 540
Fees and other revenue 1,475 1,467
Net investment income 260 218
Net realized capital losses (333 ) (1 )
Total revenue 15,165   15,693  
 
Benefits and expenses:
Health care costs 10,916 10,848
Current and future benefits 545 529
Operating expenses:
Selling expenses 421 421
General and administrative expenses 3,432   2,442  
Total operating expenses 3,853 2,863
Interest expense 173 102
Amortization of other acquired intangible assets 60 62
Loss on early extinguishment of long-term debt 246    
Total benefits and expenses 15,793   14,404  
 
(Loss) income before income taxes (628 ) 1,289
Income tax (benefit) expense (249 ) 551  
Net (loss) income including non-controlling interests (379 ) 738  
Less: Net income attributable to non-controlling interests 2   1  
Net (loss) income attributable to Aetna $ (381 ) $ 737  
 
 
Consolidated Statements of Cash Flows
(Unaudited)
 
      For the Three Months Ended
March 31,
(Millions) 2017     2016
Cash flows from operating activities:
Net (loss) income including non-controlling interests $ (379 ) $ 738
Adjustments to reconcile net income to net cash provided by
operating activities:
Net realized capital losses 333 1
Depreciation and amortization 160 169
Debt fair value amortization (7 ) (7 )
Equity in (earnings) losses of affiliates, net (38 ) 15
Stock-based compensation expense 54 54
Amortization of net investment premium 17 21
Loss on early extinguishment of long-term debt 246
Changes in assets and liabilities:
Premiums due and other receivables (477 ) (182 )
Income taxes (271 ) 519
Other assets and other liabilities (95 ) (262 )
Health care and insurance liabilities 1,356   725  
Net cash provided by operating activities 899   1,791  
Cash flows from investing activities:
Proceeds from sales and maturities of investments 2,738 2,938
Cost of investments (2,723 ) (3,060 )
Additions to property, equipment and software (71 ) (55 )
Net cash used for investing activities (56 ) (177 )
Cash flows from financing activities:
Repayment of long-term debt (11,484 )
Common shares issued under benefit plans, net (103 ) (79 )
Common shares repurchased (3,300 )
Dividends paid to shareholders (88 ) (87 )
Net payment on interest rate derivatives (206 )
Contributions, non-controlling interests 13    
Net cash used for financing activities (14,962 ) (372 )
Net (decrease) increase in cash and cash equivalents (14,119 ) 1,242
Cash and cash equivalents, beginning of period 17,996   2,524  
Cash and cash equivalents, end of period $ 3,877   $ 3,766  
 
Reconciliation of the Most Directly Comparable GAAP Measure to
Certain Reported Amounts
 
(Millions, except per common share data)               For the Three Months Ended March 31, 2017                 For the Three Months Ended March 31, 2016
Reconciliation of net (loss) income to adjusted earnings

Total
Company

   

Per
Common
Share

Total
Company

   

Per
Common
Share

Net (loss) income(1) (GAAP measure) $ (381 ) $ (1.11 ) $ 737 $ 2.08
Loss on early extinguishment of long-term debt 246 0.71
Penn Treaty-related guaranty fund assessments 231 0.67
Transaction and integration-related costs 1,212 3.50 66 0.19
Amortization of other acquired intangible assets 60 0.17 62 0.18
Net realized capital losses 333 0.96 1
Income tax benefit (762 ) (2.20 ) (45 ) (0.13 )
Dilutive share impact to adjusted earnings(5)   0.01      
Adjusted earnings(2) $ 939   $ 2.71   $ 821   $ 2.32  
 
Weighted average common shares - diluted (GAAP)(5) 343.8 353.8
Adjusted weighted average common shares - diluted (non-GAAP)(5) 346.2 353.8
 
For the Three Months Ended March 31, 2017   For the Three Months Ended March 31, 2016  
(Millions)

Health
Care

Group
Insurance

Large
Case
Pensions

Corporate
Financing(9)

Total
Company

Health
Care

Group
Insurance

Large
Case
Pensions

Corporate
Financing(9)

Total
Company

Reconciliation of total revenue to adjusted revenue
Total revenue (GAAP measure) $ 14,783 $ 621 $ 86 $ (325 ) $ 15,165 $ 15,014 $ 612 $ 67 $ $ 15,693
Interest income on proceeds of transaction-related debt (11 ) (11 )
Net realized capital (gains) losses (1 ) (2 )   336   333   6   (3 ) (2 )   1  
Adjusted revenue(3) (excludes net realized capital
(gains) losses and an other item)
$ 14,782   $ 619   $ 86   $   $ 15,487   $ 15,020   $ 609   $ 65   $   $ 15,694  
 
Reconciliation of income (loss) before income taxes to pre-tax
adjusted earnings
Income (loss) before income taxes (GAAP measure) $ 1,188 $ 35 $ 5 $ (1,856 ) $ (628 ) $ 1,391 $ 28 $ 1 $ (131 ) $ 1,289
Less: Income (loss) before income taxes attributable to
non-controlling interests (GAAP measure)
2     1     3   3     (2 )   1  
Income (loss) before income taxes attributable to Aetna (GAAP
measure)
1,186 35 4 (1,856 ) (631 ) 1,388 28 3 (131 ) 1,288
Loss on early extinguishment of long-term debt 246 246
Penn Treaty-related guaranty fund assessments 231 231
Transaction and integration-related costs 1,212 1,212 66 66
Amortization of other acquired intangible assets 60 60 62 62
Net realized capital (gains) losses (1 ) (2 )   336   333   6   (3 ) (2 )   1  
Pre-tax adjusted earnings (loss)(2) $ 1,476   $ 33   $ 4   $ (62 ) $ 1,451   $ 1,456   $ 25   $ 1   $ (65 ) $ 1,417  
 

Margins and Ratios

 
      For the Three Months
Ended March 31,
(Millions) 2017     2016
Reconciliation of (loss) income before income taxes to adjusted
earnings before income taxes, excluding interest expense:
(Loss) income before income taxes (GAAP measure) $ (628 ) $ 1,289
Interest expense(10) 88 79
Loss on early extinguishment of long-term debt 246
Penn Treaty-related guaranty fund assessments 231
Transaction and integration-related costs 1,212 66
Amortization of other acquired intangible assets 60 62
Net realized capital losses 333   1  
Adjusted earnings(2) before income taxes, excluding
interest expense
(A) $ 1,542   $ 1,497  
 
Reconciliation of net (loss) income to adjusted earnings
excluding interest expense, net of tax:
Net (loss) income (1) (GAAP measure) (B) $ (381 ) $ 737
Interest expense(10) 88 79
Loss on early extinguishment of long-term debt 246
Penn Treaty-related guaranty fund assessments 231
Transaction and integration-related costs 1,212 66
Amortization of other acquired intangible assets 60 62
Net realized capital losses 333 1
Income tax benefit (793 ) (73 )
Adjusted earnings(2) excluding interest expense, net of
tax
$ 996   $ 872  
 
Reconciliation of total revenue to adjusted revenue:
Total revenue (GAAP measure) (C) $ 15,165 $ 15,693
Interest income on proceeds of transaction-related debt (11 )
Net realized capital losses 333   1  
Adjusted revenue(3) (excludes net realized capital losses
and an other item)
(D) $ 15,487   $ 15,694  
 
Reconciliation of total operating expenses to adjusted operating
expenses:
Total operating expenses (GAAP measure) (E) $ 3,853 $ 2,863
Penn Treaty-related guaranty fund assessments (231 )
Transaction and integration-related costs (1,138 ) (43 )
Adjusted operating expenses (F) $ 2,484   $ 2,820  
 
Net (loss) income and adjusted pre-tax margins:
After-tax net (loss) income margin (GAAP measure) (B)/(C) (2.5 )% 4.7 %
Adjusted pre-tax margin(7) (A)/(D) 10.0 % 9.5 %
 
Expense ratios:
Total company expense ratio (GAAP measure) (E)/(C) 25.4 % 18.2 %
Adjusted expense ratio(6) (F)/(D) 16.0 % 18.0 %
 
 
Health Care, Group Insurance and Corporate Financing Operating
Cash Flow as a Percentage of Net Income
 
    For the Three Months
Ended March 31,
(Millions) 2017     2016
Net cash provided by operating activities (GAAP measure) $ 899 $ 1,791
Less: Net cash used for operating activities: Large Case Pensions (84 ) (63 )
Net cash provided by operating activities: Health Care, Group
Insurance and Corporate Financing
(A) 983   1,854  
 
Net (loss) income(1) (GAAP Measure) (381 ) 737
Less: Net income: Large Case Pensions 5   1  
Net (loss) income: Health Care, Group Insurance and Corporate
Financing
(B) $ (386 ) $ 736  
 
Operating cash flow as a percentage of net income:
Operating cash flow as a percentage of net income (1)
(GAAP Measure)
(A)/(B) N/M * 251.9 %

* Not meaningful due to the net loss reported for the three months ended
March 31, 2017

Footnotes

(1) Net income (loss) refers to net income (loss)
attributable to Aetna reported in Aetna's Consolidated Statements of
Income in accordance with U.S. generally accepted accounting principles
("GAAP"). Income (loss) before income taxes refers to income (loss)
before income taxes attributable to Aetna in accordance with GAAP.
Unless otherwise indicated, all references in this press release to net
income (loss), net income (loss) per share and income (loss) before
income taxes exclude amounts attributable to non-controlling interests.

(2) Effective March 31, 2017, to more clearly differentiate
between the GAAP and non-GAAP financial measures used in this press
release and Aetna's other disclosures, Aetna changed the naming
convention for its non-GAAP financial measures from "operating" measures
to "adjusted" measures. The underlying calculations of Aetna's
consolidated non-GAAP financial measures did not change. Non-GAAP
financial measures such as adjusted earnings, adjusted earnings per
share, pre-tax adjusted earnings, adjusted operating expenses, adjusted
revenue, adjusted expense ratio and adjusted pre-tax margin exclude from
the relevant GAAP metrics, as applicable:

  • Amortization of other acquired intangible assets;
  • Net realized capital gains or losses; and
  • Other items, if any, that neither relate to the ordinary course of
    Aetna's business nor reflect Aetna's underlying business performance.

Although the excluded items may recur, management believes the non-GAAP
financial measures Aetna discloses, including those described above,
provide a more useful comparison of Aetna's underlying business
performance from period to period. Prior to March 31, 2017, operating
earnings was the measure reported to the chief executive officer for
purposes of assessing financial performance and making operating
decisions, such as the allocation of resources among Aetna's business
segments. Effective March 31, 2017, the chief executive officer assesses
consolidated Aetna results based on adjusted earnings and assesses
business segment results based on pre-tax adjusted earnings because
income taxes are recorded in Aetna's Corporate Financing segment and are
not allocated to Aetna's business segments. Also effective March 31,
2017, transaction and integration-related costs were reclassified to
Aetna's Corporate Financing segment because they do not reflect Aetna's
underlying business performance. The prior period has been restated to
reflect this presentation. Non-GAAP financial measures Aetna discloses,
including those described above, should not be considered a substitute
for, or superior to, financial measures determined or calculated in
accordance with GAAP.

For the periods covered in this press release, the following items are
excluded from the non-GAAP financial measures described above, as
applicable, because Aetna believes they neither relate to the ordinary
course of Aetna's business nor reflect Aetna's underlying business
performance:

  • In the three months ended March 31, 2017, Aetna incurred losses on the
    early extinguishment of long-term debt due to (a) the mandatory
    redemption of $10.2 billion aggregate principal amount of certain of
    its senior notes issued in June 2016 (collectively, the "SMR Notes")
    following the termination of the definitive agreement (the "Humana
    Merger Agreement") to acquire Humana Inc. ("Humana") and (b) the early
    redemption of $750 million aggregate principal amount of its
    outstanding senior notes due 2020.
  • In the three months ended March 31, 2017, Aetna recorded an expense
    for estimated future guaranty fund assessments related to Penn Treaty
    Network America Insurance Company and one of its subsidiaries
    (collectively, "Penn Treaty"), which was placed in rehabilitation in
    2009 and placed in liquidation in March 2017. This expense does not
    directly relate to the underwriting or servicing of products for
    customers and is not directly related to the core performance of
    Aetna's business operations.
  • Aetna incurred transaction and integration-related costs during the
    three months ended March 31, 2017 and 2016 primarily related to its
    proposed acquisition of Humana (the "Humana Transaction"). Transaction
    costs include costs associated with the termination of the Humana
    Merger Agreement, the termination of Aetna's agreement to sell certain
    assets to Molina Healthcare, Inc. and advisory, legal and other
    professional fees which are reflected in Aetna's GAAP Consolidated
    Statements of Income in general and administrative expenses.
    Transaction costs also include the negative cost of carry associated
    with the debt financing that Aetna obtained in June 2016 for the
    Humana Transaction. Prior to the mandatory redemption of the SMR
    Notes, the negative cost of carry associated with these senior notes
    was excluded from adjusted earnings and pre-tax adjusted earnings. The
    negative cost of carry associated with the $2.8 billion aggregate
    principal amount of Aetna's senior notes issued in June 2016 that are
    not subject to mandatory redemption (the "Other 2016 Senior Notes")
    was excluded from adjusted earnings and pre-tax adjusted earnings
    through the date of the termination of the Humana Merger Agreement.
    The components of the negative cost of carry are reflected in Aetna's
    GAAP Consolidated Statements of Income in interest expense and net
    investment income. Subsequent to the termination of the Humana Merger
    Agreement, the interest expense and net investment income associated
    with the Other 2016 Senior Notes were no longer excluded from adjusted
    earnings and pre-tax adjusted earnings.
  • Other acquired intangible assets relate to Aetna's acquisition
    activities and are amortized over their useful lives. However, this
    amortization does not directly relate to the underwriting or servicing
    of products for customers and is not directly related to the core
    performance of Aetna's business operations.
  • Net realized capital gains and losses arise from various types of
    transactions, primarily in the course of managing a portfolio of
    assets that support the payment of liabilities. However, these
    transactions do not directly relate to the underwriting or servicing
    of products for customers and are not directly related to the core
    performance of Aetna's business operations.
  • The corresponding tax benefit or expense related to the items excluded
    from adjusted earnings discussed above. The tax benefit or expense was
    calculated utilizing the appropriate tax rate for each individual item
    excluded from adjusted earnings.

For a reconciliation of financial measures calculated under GAAP to
these items, refer to the tables on pages 10 through 11 of this press
release.

(3) Adjusted revenue excludes net realized capital gains and
losses and interest income on the proceeds of Aetna's senior notes
issued in June 2016 as noted in (2) above. Refer to the
tables on pages 10 through 11 of this press release for a reconciliation
of total revenue calculated under GAAP to adjusted revenue.

(4) Projected full-year 2017 net income per share and
adjusted earnings per share reflect a range of 334 million to 335
million weighted average diluted shares. Projected full-year 2017
adjusted earnings per share exclude from projected full-year 2017 net
income per share the loss on early extinguishment of long-term debt, the
projected Penn Treaty-related guaranty fund assessments, projected
transaction and integration-related costs (including termination costs)
primarily related to the Humana Transaction, estimated amortization of
other acquired intangible assets, net realized capital gains and losses,
other items, if any, that neither relate to the ordinary course of
Aetna's business nor reflect Aetna's underlying business performance and
the corresponding income tax benefit or expense related to the items
excluded from net income per share discussed above. Amortization of
other acquired intangible assets relates to Aetna's acquisition
activities. The table below reconciles projected 2017 net income per
share to projected 2017 adjusted earnings per share:

 
Reconciliation of Projected 2017 Net Income Per Share to
Projected 2017 Adjusted Earnings Per Share
Projected net income per share (GAAP measure)     $4.48 to $4.68
Loss on early extinguishment of long-term debt .74
Penn Treaty-related guaranty fund assessments .69
Transaction and integration-related costs (including termination
costs)
3.69
Amortization of other acquired intangible assets .70
Net realized capital losses 1.00
Income tax benefit (2.50)
Projected adjusted earnings per share $8.80 to $9.00
 

Aetna will experience net realized capital gains or net realized capital
losses during the remainder of 2017, however Aetna cannot project the
amount of such future gains or losses. Therefore, Aetna has assumed no
net realized capital gains or losses after March 31, 2017 for purposes
of projecting net income and net income per share. Aetna's annual net
realized capital gains or losses ranged from a net realized capital loss
of $65 million to a net realized capital gain of $86 million during
calendar years 2014 through 2016.

(5) In periods when Aetna reports a net loss attributable to
Aetna, in-the-money stock-based compensation awards are excluded from
Aetna's calculation of diluted earnings per share ("EPS") because their
inclusion would have an anti-dilutive effect. Therefore Aetna excluded
from its first-quarter 2017 GAAP net loss per share calculation
in-the-money stock-based compensation awards which would have increased
Aetna's weighted-average shares used to compute diluted EPS by 2.4
million shares. Aetna reported adjusted earnings for first-quarter 2017.
Therefore such 2.4 million shares were included in Aetna's calculation
of adjusted EPS for first-quarter 2017 because they had a dilutive
effect on Aetna's adjusted EPS.

(6) The adjusted expense ratio excludes net realized capital
gains and losses and other items, if any, that are excluded from
adjusted revenue or adjusted operating expenses, as noted in (2)
above. For a reconciliation of the comparable GAAP measure to this
metric for the periods covered by this press release, refer to page 11
of this press release.

(7) In order to provide useful information regarding Aetna's
profitability on a basis comparable to others in the industry, without
regard to financing decisions, income taxes or amortization of other
acquired intangible assets (each of which may vary for reasons not
directly related to the performance of the underlying business), Aetna's
adjusted pre-tax margin is based on adjusted earnings excluding interest
expense and income taxes. Management also uses the adjusted pre-tax
margin to assess Aetna's performance, including performance versus
competitors.

(8) Days claims payable is calculated by dividing the health
care costs payable at each quarter end by the average health care costs
per day in each respective quarter. The total debt to consolidated
capitalization ratio is calculated by dividing total long-term debt and
short-term debt ("Total Debt") by the sum of Total Debt and total Aetna
shareholders' equity.

(9) Aetna's Corporate Financing segment is not a business
segment. It is added to Aetna's business segments to reconcile segment
reporting to Aetna's consolidated results. The Corporate Financing
segment includes interest expense on Aetna's outstanding debt and the
financing components of Aetna's pension and other postretirement
employee benefit plan expenses (benefits), and, effective March 31,
2017, all transaction and integration-related costs and income taxes.
The prior period has been restated to reflect this presentation. As
described in (2) above, the adjusted earnings of the
Corporate Financing segment exclude other items, if any, that neither
relate to the ordinary course of Aetna's business nor reflect Aetna's
underlying business performance.

(10) Interest expense included in the reconciliation to
adjusted earnings before income taxes, excluding interest expense and
the reconciliation to adjusted earnings excluding interest expense, net
of tax for the three months ended March 31, 2017 and 2016 excludes costs
associated with the term loan credit agreement executed in connection
with the Humana Transaction. Interest expense for the three months ended
March 31, 2017 excludes the negative cost of carry on
transaction-related debt incurred in connection with the Humana
Transaction. Interest expense for the three months ended March 31, 2016
excludes costs associated with bridge credit agreement executed in
connection with the Humana Transaction. These costs are included within
transaction and integration-related costs. Refer to (2) above
for further discussion.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You can
generally identify forward-looking statements by the use of
forward-looking terminology such as "anticipate," "believe," "continue,"
"could," "estimate," "expect," "explore," "evaluate," "intend," "may,"
"might," "plan," "potential," "predict," "project," "seek," "should," or
"will," or the negative thereof or other variations thereon or
comparable terminology. These forward-looking statements are only
predictions and involve known and unknown risks and uncertainties, many
of which are beyond Aetna's control.

Statements in this press release regarding Aetna that are
forward-looking, including Aetna's projections as to net income per
share, adjusted earnings per share, Penn Treaty-related guaranty fund
assessments, transaction and integration-related costs, amortization of
other acquired intangible assets, the income tax benefit related to
items excluded from adjusted earnings, weighted average diluted shares
(including the impact of accelerated share repurchase agreements), and
future operating results, are based on management's estimates,
assumptions and projections, and are subject to significant
uncertainties and other factors, many of which are beyond Aetna's
control. Important risk factors could cause actual future results and
other future events to differ materially from those currently estimated
by management, including, but not limited to: significant disruptions in
the market for Aetna's common shares and/or financial markets;
unanticipated increases in medical costs (including increased intensity
or medical utilization as a result of flu or otherwise; changes in
membership mix to higher cost or lower-premium products or membership
adverse selection; medical cost increases resulting from unfavorable
changes in contracting or re-contracting with providers (including as a
result of provider consolidation and/or integration); increased pharmacy
costs (including in Aetna's public health insurance exchange products));
the profitability of Aetna's individual products, where membership is
higher than Aetna previously projected and has had and may continue to
have more adverse health status and/or higher medical benefit
utilization than Aetna projected; any suspension of the ACA's health
insurer fee for 2018; adverse impacts from any failure to raise the U.S.
Federal government's debt ceiling or any sustained U.S. Federal
government shut down; and changes in Aetna's future cash requirements,
capital requirements, results of operations, financial condition and/or
cash flows. As currently enacted, health care reform will continue to
significantly impact Aetna's business operations and financial results,
including Aetna's pricing and medical benefit ratios, and key components
of the legislation will continue to be phased in through 2020. Aetna
will be required to dedicate material resources and incur material
expenses during 2017 to implement health care reform. Significant parts
of the legislation, including aspects of nondiscrimination requirements,
continue to evolve through the promulgation of regulations and guidance.
In addition, pending efforts in the U.S. Congress to repeal, amend,
replace or restrict funding for various aspects of health care reform
and pending litigation challenging aspects of the law continue to create
additional uncertainty about the ultimate impact of health care reform.
As a result, many of the impacts of health care reform are unknown.
Other important risk factors include: adverse changes in federal or
state government policies, legislation or regulations (including
legislative, judicial or regulatory measures that would affect Aetna's
business model, repeal, restrict funding for or amend various aspects of
health care reform, limit Aetna's ability to price for the risk it
assumes and/or reflect reasonable costs or profits in its pricing, such
as mandated minimum medical benefit ratios, or eliminate or reduce ERISA
pre-emption of state laws (increasing Aetna's potential litigation
exposure)); uncertainty related to Aetna's accruals for the ACA's
reinsurance, risk adjustment and risk corridor programs ("3R's");
uncertainty related to the funding for and final reconciliations with
respect to the ACA's risk management and subsidy programs; the
implementation of health care reform legislation, collection of ACA
fees, assessments and taxes through increased premiums; adverse
legislative, regulatory and/or judicial changes to or interpretations of
existing health care reform legislation and/or regulations (including
those relating to minimum medical loss ratio ("MLR") rebates); the
implementation of public health insurance exchanges; the timing and
amount of and payment methods for satisfying assessments for Penn Treaty
Network America Insurance Company and other insolvent payors under state
guaranty fund laws; adverse and less predictable economic conditions in
the U.S. and abroad (including unanticipated levels of, or increases in
the rate of, unemployment); reputational or financial issues arising
from Aetna's social media activities, data security breaches, other
cybersecurity risks or other causes; Aetna's ability to diversify
Aetna's sources of revenue and earnings (including by developing and
expanding Aetna's consumer business and expanding Aetna's foreign
operations), transform Aetna's business model, develop new products and
optimize Aetna's business platforms; the success of Aetna's consumer
health and services initiatives; adverse changes in size, product or
geographic mix or medical cost experience of membership; managing
executive succession and key talent retention, recruitment and
development; failure to achieve and/or delays in achieving desired rate
increases and/or profitable membership growth due to regulatory review
or other regulatory restrictions, an uncertain economy and/or
significant competition, especially in key geographic areas where
membership is concentrated, including successful protests of business
awarded to Aetna; failure to adequately implement health care reform
and/or repeal of or changes in health care reform; the outcome of
various litigation and regulatory matters, including audits, challenges
to Aetna's minimum MLR rebate methodology and/or reports, intellectual
property litigation and litigation concerning, and ongoing reviews by
various regulatory authorities of, certain of Aetna's payment practices
with respect to out-of-network providers, other providers and/or life
insurance policies; Aetna's ability to integrate, simplify, and enhance
Aetna's existing products, processes and information technology systems
and platforms to keep pace with changing customer and regulatory needs;
Aetna's ability to successfully integrate Aetna's businesses (including
businesses Aetna may acquire in the future) and implement multiple
strategic and operational initiatives simultaneously; Aetna's ability to
manage health care and other benefit costs; adverse program, pricing,
funding or audit actions by federal or state government payors,
including as a result of sequestration and/or changes to or curtailment
or elimination of the Centers for Medicare & Medicaid Services' ("CMS")
star rating bonus payments; Aetna's ability to maintain and/or enhance
its CMS star ratings; Aetna's ability to reduce administrative expenses
while maintaining targeted levels of service and operating performance;
failure by a service provider to meet its obligations to Aetna; Aetna's
ability to develop and maintain relationships (including joint ventures
or other collaborative risk-sharing agreements) with providers while
taking actions to reduce medical costs and/or expand the services Aetna
offers; Aetna's ability to demonstrate that Aetna's products and
processes lead to access to quality affordable care by Aetna's members;
Aetna's ability to maintain its relationships with third-party brokers,
consultants and agents who sell its products; increases in medical costs
or Group Insurance claims resulting from any epidemics, acts of
terrorism or other extreme events; changes in medical cost estimates due
to the necessary extensive judgment that is used in the medical cost
estimation process, the considerable variability inherent in such
estimates, and the sensitivity of such estimates to changes in medical
claims payment patterns and changes in medical cost trends; and a
downgrade in Aetna's financial ratings. For more discussion of important
risk factors that may materially affect Aetna, please see the risk
factors contained in Aetna's 2016 Annual Report on Form 10-K ("Aetna's
2016 Annual Report"), on file with the Securities and Exchange
Commission ("SEC"), and Aetna's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017 ("Aetna's Quarterly Report"), when filed
with the SEC. You should also read Aetna's 2016 Annual Report and
Aetna's Quarterly Report for a discussion of Aetna's historical results
of operations and financial condition.

No assurances can be given that any of the events anticipated by the
forward-looking statements will transpire or occur, or if any of them do
occur, what impact they will have on the results of operations,
financial condition or cash flows of Aetna. Aetna does not assume any
duty to update or revise forward-looking statements, whether as a result
of new information, future events or otherwise, as of any future date.

 

Supplementary Information

 
Statements of Income Before Income Taxes Attributable to Aetna by
Segment (Unaudited)
 
    Health   Group   Large Case   Corporate  
(Millions) Care Insurance Pensions Financing Total
For the three months ended March 31, 2017
Revenue:
Health care premiums $ 13,219 $ $ $ $ 13,219
Other premiums 531 13 544
Fees and other revenue 1,448 25 2 1,475
Net investment income 115 63 71 11 260
Net realized capital gains (losses) 1   2     (336 ) (333 )
Total revenue 14,783   621   86   (325 ) 15,165  
Benefits and expenses:
Health care costs 10,916 10,916
Current and future benefits 467 78 545
Operating expenses:
Selling expenses 384 37 421
General and administrative expenses 2,235   82   3   1,112   3,432  
Total operating expenses 2,619 119 3 1,112 3,853
Interest expense 173 173
Amortization of other acquired intangible assets 60 60
Loss on early extinguishment of long-term debt       246   246  
Total benefits and expenses 13,595   586   81   1,531   15,793  
Income (loss) before income taxes including non-controlling interests 1,188   35   5   (1,856 ) (628 )
Less: Income before income taxes attributable to non-controlling
interests
2     1     3  
Income (loss) before income taxes attributable to Aetna $ 1,186   $ 35   $ 4   $ (1,856 ) $ (631 )
 
For the three months ended March 31, 2016
Revenue:
Health care premiums $ 13,469 $ $ $ $ 13,469
Other premiums 525 15 540
Fees and other revenue 1,439 26 2 1,467
Net investment income 112 58 48 218
Net realized capital (losses) gains (6 ) 3   2     (1 )
Total revenue 15,014   612   67     15,693  
Benefits and expenses:
Health care costs 10,848 10,848
Current and future benefits 466 63 529
Operating expenses:
Selling expenses 390 31 421
General and administrative expenses 2,323   87   3   29   2,442  
Total operating expenses 2,713 118 3 29 2,863
Interest expense 102 102
Amortization of other acquired intangible assets 62         62  
Total benefits and expenses 13,623   584   66   131   14,404  
Income (loss) before income taxes including non-controlling interests 1,391   28   1   (131 ) 1,289  
Less: Income (loss) before income taxes attributable to
non-controlling interests
3     (2 )   1  
Income (loss) before income taxes attributable to Aetna $ 1,388   $ 28   $ 3   $ (131 ) $ 1,288  
 
 
Membership
 
    March 31, 2017     December 31, 2016     March 31, 2016
(Thousands) Insured     ASC     Total Insured     ASC     Total Insured     ASC     Total
Medical Membership:  
Commercial 4,557 13,351 17,908 5,457 13,132 18,589 5,792 12,931 18,723
Medicare Advantage 1,443 1,443 1,362 1,362 1,332 1,332
Medicare Supplement 711 711 685 685 612 612
Medicaid 1,570   814   2,384   1,668   806   2,474   1,549   773   2,322
Total Medical Membership 8,281   14,165   22,446   9,172   13,938   23,110   9,285   13,704   22,989
 
Dental Membership:
Total Dental Membership 5,898   8,116   14,014   6,086   8,386   14,472   5,913   8,392   14,305
 
Pharmacy Benefit Management Services Membership:
Commercial 8,217 9,400 9,767
Medicare Prescription Drug Plan (stand-alone) 2,064 2,067 1,939
Medicare Advantage Prescription Drug Plan 1,106 953 934
Medicaid 2,817   2,783   2,602
Total Pharmacy Benefit Management Services Membership 14,204   15,203   15,242
 
Health Care Medical Benefit Ratios
 
    For the Three Months Ended
March 31,
(Millions) 2017     2016
Premiums (GAAP measure)
Commercial $ 6,109 $ 6,964
Government 7,110   6,505  
Health Care $ 13,219   $ 13,469  
Health Care Costs (GAAP measure)
Commercial $ 4,848 $ 5,420
Government 6,068   5,428  
Health Care $ 10,916   $ 10,848  
Medical Benefit Ratios "MBRs"
Commercial 79.4 % 77.8 %
Government 85.3 % 83.4 %
Health Care 82.6 % 80.5 %
 
 
Roll Forward of Health Care Costs Payable
(Unaudited)
 
    For the Three Months Ended March 31,
(Millions) 2017     2016
Health care costs payable, beginning of period $ 6,558 $ 6,306
Less: reinsurance recoverables 5   4  
Health care costs payable, beginning of period, net 6,553 6,302
Add: Components of incurred health care costs:
Current year 11,420 11,475
Prior years(a) (614 ) (627 )
Total incurred health care costs (b) 10,806 10,848
 
Less: Claims paid
Current year 6,298 5,929
Prior years 4,742   4,398  
Total claims paid 11,040 10,327
 
Health care costs payable, end of period, net 6,319 6,823
Add: premium deficiency reserve 110
Add: reinsurance recoverables 3   2  
Health care costs payable, end of period $ 6,432   $ 6,825  

(a) Negative amounts reported for incurred health care costs
related to prior years result from claims being settled for less than
originally estimated.
(b) Total incurred health care
costs exclude from the table above $110 million related to the premium
deficiency reserve recorded during first-quarter 2017 for the 2017
coverage year on Aetna's Individual Commercial products.

 
Days Claims Payable (Unaudited)
 
    March 31, 2017     December 31, 2016     September 30, 2016     June 30, 2016     March 31, 2016
Days Claims Payable 53 54 57 56 57
 
Health Care Reform's Reinsurance, Risk Adjustment and Risk
Corridor (the "3Rs")
(a) Net Receivable (Payable)
 
    At March 31, 2017     At December 31, 2016
(Unaudited)        
(Millions) Reinsurance     Risk Adjustment     Risk Corridor(b) Reinsurance Risk Adjustment Risk Corridor
Current $ 166 $ (696 ) $ 1 $ 202 $ (690 ) $ (10 )
Long-term 12   (38 )        
Total net receivable (payable) $ 178   $ (734 ) $ 1   $ 202   $ (690 ) $ (10 )

(a) Aetna participates in certain public health insurance
exchanges established pursuant to the Patient Protection and Affordable
Care Act and the Health Care and Education Reconciliation Act of 2010
(as amended, collectively, "Health Care Reform" or the "ACA"). Under
regulations established by the U.S. Department of Health and Human
Services ("HHS"), HHS pays Aetna a portion of the premium and a portion
of the health care costs for low-income individual Public Exchange
members. In addition, HHS administers the 3Rs risk management programs.
The ACA's temporary Reinsurance and Risk Corridor programs expired at
the end of 2016.
(b) At March 31, 2017, Aetna estimates
that it is entitled to receive a total of $529 million from HHS under
the three-year ACA risk corridor program for the 2014 through 2016
program years. At March 31, 2017, Aetna did not record any ACA risk
corridor receivables related to the 2016 or 2015 program years or any
amount in excess of HHS's announced prorated funding amount for the 2014
program year, because payments from HHS are uncertain.

View Comments and Join the Discussion!
 

Partner Center